Experience
Elan Pharmaceuticals
KV Pharmaceuticals (Paradissis)
We assisted our client Elan Pharmaceuticals in obtaining a judgment against Paradissis based on the benefit of the earlier filing date of Elan’s foreign priority application. The subject involved controlled-release pharmaceutical formulation for once-per-day administration.
Elan Pharmaceuticals v. KV Pharmaceuticals (Paradissis), Int. No. 104,617, BPAI, Sprizzo
Startup sold to major drug company based on strength of patents
Agouron Pharmaceuticals, Inc.
Assisted on a successful claim for an Arrow declaration on behalf of a major pharmaceutical company*
Patent ownership and licensing dispute dismissed on summary judgment for computer graphics company
S3 Graphics Co. Ltd.
Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.
Eli Lilly and Company
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.